Vimta Labs Ltd. (VIMTALABS) — Tipsheet

Vimta Labs lands first biologics order, budgets ₹80 cr capex for FY27

Tipsheet Editorial — Mon, 20 Jul 2026 17:06:51 GMT

Q1 results were already disclosed; the concall adds the domestic biologics win and a ₹80 cr capex plan, including ₹10 cr for the new unit.

What’s new

First biologics services order from a domestic customer, facility now operational.
Capex budget of ₹80 cr for FY27, with ₹10 cr earmarked for the biologics unit.
EBITDA margin moderated sequentially due to facility costs and rupee appreciation, but management expects it to hold.

Why it matters

Biologics is a new growth vector for Vimta and the first order validates the investment. The ₹80 cr capex signals confidence in the medium-term outlook, even if Q1 margins took a temporary hit. Execution on the biologics pipeline will be the key swing factor.

What we’re watching

Size and ramp of the biologics order book over the next two quarters.
Whether EBITDA margin can stabilize at the ~36% level seen in Q1.
Recovery in food testing as global trade disruptions ease.

The full read

Vimta Labs' Q1 numbers were already out — revenue up 13.7% to ₹1,129 million, EBITDA at 36.4%. The concall added colour, not new math. What stood out: the first biologics services order from a domestic customer and a ₹80 crore FY27 capex plan that includes ₹10 crore for the biologics unit. Margins slipped sequentially on facility costs and rupee strength, but management expects them to hold. Food testing remains under pressure from global trade disruption, though domestic demand is cushioning the fall. Vimta is net debt-free and cautiously optimistic. The biologics order is a genuine new vector; the capex says management believes in it. Execution is all that matters from here.

Primary source: BSE · NSE

Vimta Labs Q1 revenue up 13.7%, EBITDA margin at 36.4%

Tipsheet Editorial — Mon, 20 Jul 2026 15:29:02 GMT

Steady pharma testing demand and domestic gains offset food testing weakness. Entry into biologics CRD adds a long-term growth lever.

What’s new

Total income of ₹1,129M, up 13.7% YoY
Net profit at ₹210M, EBITDA margin expands to 36.4%
Company completed a Ukraine regulatory audit and commenced biologics contract R&D services

Why it matters

A 36.4% EBITDA margin in a mixed demand environment signals cost discipline and pricing power in pharma testing. The biologics entry, while nascent, broadens the addressable market beyond small molecules. But food testing headwinds from global uncertainties remain a drag.

What we’re watching

Revenue trajectory from the biologics CRD business over the next 2-3 quarters
Recovery in the food testing division as global conditions evolve
Sustainability of EBITDA margins above 35%

The full read

Vimta Labs delivered a solid quarter. ₹1,129M in total income, up 13.7% YoY. EBITDA margin hit 36.4%, one of its highest in recent periods. The pharma testing business drove the show, while the food testing division, though hit by global uncertainties, was rescued by domestic demand. Two operational milestones: a completed Ukraine audit and the commencement of biologics CRD services. They add incremental depth but won't move the needle immediately. The margin strength is the real headline, in a sector where pricing and utilisation matter more than top-line growth. The open question is how long that holds as the biologics ramp-up and food testing recovery play out.

Primary source: BSE · NSE

Vimta Labs Q1: Revenue up 12%, PAT up 11% — steady but not a catalyst

Tipsheet Editorial — Mon, 20 Jul 2026 13:44:27 GMT

In-line quarter with single-digit profit growth; no guidance change. ESOP grant routine.

What’s new

Revenue up 12% YoY to ₹1,090.74 million; PAT up 11% to ₹210.42 million.
Auditors issued unmodified limited review report.
Board approved 40,500 stock options under ESOP plan.

Why it matters

The quarter continues Vimta's steady run but offers no new catalyst. With no guidance revision or strategic announcement, the stock's 34.5x trailing P/E leaves little room for error if growth falters.

What we’re watching

Whether revenue growth accelerates from the current 12% pace.
Any large contract wins in the CRO testing space.
ESOP dilution impact, though 40,500 options are immaterial.

The full read

Vimta Labs' Q1 FY27 numbers are textbook continuation: revenue of ₹1,090.74 million up 12% year-on-year, profit of ₹210.42 million up 11%. The auditor signed off without modification, and the board handed out 40,500 stock options, too small to move the needle on a ₹2,671 cr market cap. The analyst call is routine, in-line, no guidance, no surprise. That is the problem. At 34.5x trailing earnings, the market is paying for acceleration. Vimta delivered consistency. Consistency alone rarely justifies the multiple.

Primary source: BSE · NSE